Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACOS
NCT05019703Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, cabozantinib in osteosarcoma (OS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2023; status: recruiting.
02
Drugs
atezolizumabcabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05019703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019703.